Sanyo Trading (3176) FY2026 Q1 Earnings Report

Quick View

Executive Summary

In Q1 of the fiscal year ending September 2026, the core business posted slight declines in revenue and profit, while extraordinary gains led to a substantial increase in net income. Revenue was ¥33.84B (-0.4% YoY), Operating Income was ¥1.89B (-2.3%), and Ordinary Income was ¥2.22B (-13.0%), with the decline in profit widening at each level. Meanwhile, Net Income was ¥2.04B (+38.0%), primarily due to ¥1.01B in extraordinary gains, including ¥0.94B in gains on the sale of investment securities; this does not indicate an improvement in the profitability of the core business. Progress against the full-year plan was 26.0% for revenue and 30.4% for Operating Income, exceeding the standard 25%, indicating solid progress in the core business.

Factors Affecting Performance

【Revenue】Revenue was ¥33.84B, essentially flat at -0.4% YoY. Industrial Products, the main business, achieved revenue growth of +0.6%, while Life Science declined -3.3% due to the impact of the termination of biotechnology-related contracts, offsetting the overall result. Sustainability grew +11.5% due to the recognition of a large-scale woody biomass project, but its small scale limited its impact on consolidated revenue.

【Profit and Loss】Operating Income was ¥1.89B, down -2.3% YoY. Although the gross margin improved to 17.4% from 17.0% in the same period of the previous year due to an improvement in the cost-of-sales ratio, SG&A expenses increased +3.5%, putting pressure on profit. Ordinary Income was ¥2.22B, down -13.0%, declining more than Operating Income. This was apparently affected by a decrease in non-operating income, such as foreign exchange gains, recorded in the same period of the previous year. Net Income of ¥2.04B represented a temporary increase driven by ¥1.01B in extraordinary gains, including ¥0.94B in gains on the sale of investment securities. The divergence between Ordinary Income and Net Income was attributable to factors outside the core business. In conclusion, the company experienced declines in revenue and profit on a core-business basis, while Net Income increased due to extraordinary factors.

Segment Analysis

The main business was Industrial Products, which generated Operating Income of ¥0.87B and had the largest composition ratio; its increase in revenue and profit (revenue +0.6%, profit +3.3%) supported consolidated performance. Fine Chemicals saw revenue decline (-1.8%), but profit increased (+2.6%) due to price revisions. Meanwhile, Life Science posted a significant decline in profit, with revenue down -3.3% and Operating Income down -22.9%, becoming a drag on consolidated profit. Sustainability also increased revenue but reported a -12.8% decline in profit due to a gap period in the marine development business. Profit margins were relatively high for Industrial Products at 8.9% and Sustainability at 9.5%, while Life Science was relatively low at 4.8%.

Key Financial Metrics

Profitability: ROE 3.9% (quarterly result), Operating Income margin 5.6%
Cash quality: Cash and deposits of ¥11.51B and interest-bearing debt of ¥3.75B, indicating a net cash financial structure
Investment efficiency: Goodwill of ¥1.91B (newly recognized through acquisitions including EMAS)
Financial soundness: Equity Ratio of 63.1%, current ratio of 247.1% (current assets of ¥71.71B/current liabilities of ¥29.02B)

Cash Flow Analysis

Quality of Earnings

Ordinary Income of ¥2.22B and Net Income of ¥2.04B were similar, but Profit Before Tax was ¥3.23B. The ¥1.01B difference from Ordinary Income was attributable to extraordinary gains, including ¥0.94B in gains on the sale of investment securities. Of ¥0.38B in non-operating income, foreign exchange gains accounted for ¥0.31B. Although this was less than 1% of revenue, it represented approximately 14% of Ordinary Income (¥2.22B) and cannot be ignored as a factor affecting Ordinary Income. The increase in Net Income depended on extraordinary gains, while Operating Income and Ordinary Income were both trending downward; accordingly, the quality of earnings is assessed as having a significant contribution from temporary factors.

Earnings Forecast and Guidance

Progress in Q1 against the full-year forecast (revenue of ¥130B, Operating Income of ¥6.2B, and Ordinary Income of ¥6.5B) was 26.0% for revenue, 30.4% for Operating Income, and 34.1% for Ordinary Income, all exceeding the standard progress rate of 25%. Ordinary Income in particular was +9.1pt above the standard pace, potentially reflecting the contribution of non-operating income such as foreign exchange gains. The full-year plan remains unchanged, with no revisions made.

Shareholder Returns

The annual dividend forecast is ¥58.00 (an increase from the previous year's actual year-end-equivalent dividend of ¥28.00). Based on forecast Net Income of ¥4.10B and average shares outstanding during the period of 28,810 thousand shares, the Payout Ratio is approximately 40.8%. Retained earnings of ¥47.04B and cash and deposits of ¥11.51B exceed interest-bearing debt of ¥3.75B, providing financial support for the dividend.

Catalysts

【Short term】The key points for earnings trends will be the extent to which the impact of contract terminations in the Life Science business runs its course and the timing of recovery in Sustainability's marine development projects. 【Long term】The medium-term focus will be the degree of profit contribution from overseas business expansion following the consolidation of EMAS (Singapore), as well as trends in the amortization and impairment of ¥1.91B in goodwill.

Industry Benchmark (For Reference; Prepared by the Company)

Industry Benchmark (trading)

Profitability and Returns

The Net Income Margin is below the industry median, but the gap may widen further on an underlying basis excluding extraordinary gains.

Growth and Capital Efficiency

Revenue growth is significantly below the industry median, placing the company at a competitive disadvantage within the industry in terms of top-line growth.

※Source: Prepared by the Company

Risk Factors

1. Inventory accumulation risk: Inventories of ¥28.09B account for 33.6% of total assets, and DIO has extended to approximately 93 days. Finished goods inventory accounts for the majority, creating the risk of valuation losses or discounted sales if demand slows.

2. Low-margin structure: Although the gross margin of 17.4% improved from the previous year, it remains low, and fluctuations in procurement and selling prices have a relatively significant impact on the profit margin.

3. Variability in segment profitability: The Life Science Operating Income Margin of 4.8% is low compared with other segments. If the impact of the termination of biotechnology-related contracts continues, it could weigh on the consolidated profit margin.

Key Takeaways from the Results

1. Although Operating Income and Ordinary Income declined, progress against the full-year plan exceeded the standard pace in both cases, indicating that progress in the core business itself remains solid.

2. The substantial increase in Net Income was attributable to extraordinary gains, primarily gains on the sale of investment securities, and should be distinguished from an improvement in recurring earnings power.

3. Goodwill of ¥1.91B was newly recognized through the consolidation of EMAS. The effects of overseas business expansion and trends in goodwill amortization and impairment will be areas of focus going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,721–¥1,820 at ±1% for the cost of equity, and ¥1,767–¥1,771 at ±0.1 for ω.

Notes:

• Because Net Income progress against the full-year forecast is 50%, exceeding the standard pace of 25%, forecast EPS has been adjusted upward within a maximum range of +10% (because companies progressing ahead of schedule tend to exceed forecasts. Adjustments may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below Book Value per Share.
• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat on the high side.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated through AI-based integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q1 performance was mixed: core operating earnings softened modestly, while reported net income rose sharply on sizable securities-sale gains. Revenue was ¥33.84bn, down 0.4% YoY, indicating broadly flat top-line trading activity. Operating income declined 2.3% YoY to ¥1.89bn. The operating margin was 5.6%, down approximately 11bp from 5.7% a year earlier. Gross profit increased 1.6% YoY to ¥5.88bn despite the small sales decline. Accordingly, gross margin expanded by roughly 34bp to 17.4% from 17.0%. SG&A increased 3.5% YoY to ¥4.00bn, outpacing revenue and absorbing the gross-profit improvement. Ordinary income fell 13.0% YoY to ¥2.22bn, with foreign-exchange gains declining to ¥0.31bn from ¥0.55bn. Net income nevertheless increased 37.9% YoY to ¥2.04bn. The principal driver was ¥1.01bn of extraordinary income, including a ¥0.94bn gain on sales of investment securities. This non-recurring gain lifted the net margin to 6.0%, approximately 168bp above the prior-year level, and makes the headline profit growth materially stronger than recurring earnings growth. Annualized ROE was 15.5%, supported by a 6.0% net margin, annualized asset turnover of 1.618x, and 1.59x financial leverage. The balance sheet remains liquid, with a 247.1% current ratio and cash covering short-term debt by 3.15x. However, inventories rose 8.0% YoY to ¥28.09bn and inventory days of 92-93 days exceed the stated alert thresholds. The company also completed acquisitions that increased goodwill by ¥1.22bn YoY and intangible assets by ¥1.21bn YoY. Q1 operating-income progress against the full-year plan was 30.4%, above the standard 25% seasonal benchmark, whereas profit attributable to owners reached 49.8% of the annual forecast because of the securities-sale gain. The key implication is that the company is tracking ahead of plan operationally at Q1, but sustained full-year earnings delivery depends on stabilizing ordinary-income drivers, maintaining gross-margin improvement, and converting the enlarged inventory base efficiently.

Profitability Analysis

The annualized DuPont decomposition is 15.5% ROE = 6.0% net profit margin × 1.618x asset turnover × 1.59x financial leverage. The largest period-on-period change in reported profitability is the net margin expansion, but it was principally caused by ¥1.01bn of extraordinary income rather than an improvement in recurring operations. Specifically, gains on sales of investment securities accounted for ¥0.94bn of extraordinary income, with gains on asset sales contributing ¥0.07bn. Recurring operating performance was softer: revenue declined 0.4% and operating income declined 2.3%. Gross margin improved to 17.4% from approximately 17.0%, demonstrating favorable gross-profit resilience despite broadly flat sales. This gain was more than offset at the operating level because SG&A rose 3.5%, faster than revenue. The resulting operating margin compressed to 5.6% from approximately 5.7%. The 17.4% gross margin triggers the low-gross-margin quality alert; thin gross margins are structurally common in specialized trading and distribution businesses, but they leave earnings sensitive to procurement conditions, mix, foreign exchange, and operating-cost discipline. Interest coverage was very strong at 94.35x, and interest expense was only ¥0.20bn, so debt servicing is not constraining profitability. The extended DuPont interest burden of 1.712x exceeds 1.0x because profit before tax included extraordinary gains; it should not be interpreted as recurring financing support. The tax burden was 0.632, reflecting an effective tax rate of 36.8%, which reduced conversion of pre-tax profit into net income. Segment profitability identifies Industrial Products as the core business by segment-profit contribution, generating ¥0.87bn of segment profit on ¥9.70bn of external sales. Its segment profit rose 3.2% YoY and its margin improved to 8.9% from 8.4%. Fine Chemicals generated ¥0.73bn of profit, up 2.7% YoY, on sales down 1.8% YoY. Sustainability revenue grew 11.6% YoY to ¥2.70bn, but segment profit fell 13.1% to ¥0.26bn and margin declined to 9.5% from 11.8%. Life Science sales fell 3.3% YoY and segment profit declined 22.8% to ¥0.48bn, with margin compressing to 4.8% from 6.1%.

Growth Assessment

Revenue was effectively stable in Q1, with a 0.4% YoY decline to ¥33.84bn, while the full-year forecast assumes a 2.0% YoY sales decline to ¥130.0bn. Q1 sales represented 26.0% of the full-year forecast, slightly above the 25% standard first-quarter progress rate. Operating income of ¥1.89bn represented 30.4% of the ¥6.20bn full-year plan, 5.4 percentage points above the standard Q1 progress rate. Ordinary income of ¥2.22bn represented 34.1% of the ¥6.50bn plan, also ahead of the standard seasonal run rate. Profit attributable to owners of ¥2.04bn represented 49.8% of the ¥4.10bn full-year forecast, far above the standard rate because Q1 included ¥1.01bn of extraordinary gains. Therefore, the net-income progress rate does not represent a comparable run-rate indicator for recurring earnings. Industrial Products and Fine Chemicals provided the most favorable operating-profit momentum, while Life Science was the largest drag on segment-profit growth. Sustainability delivered the strongest sales growth, but its declining margin indicates that growth has not yet translated into proportionate earnings expansion. The Q1 acquisition of EMAS SUPPLIES & SERVICES PTE. LTD. adds scale to Industrial Products, while the acquisition of Kyushu Mitaka adds to Life Science. These acquisitions may support future revenue breadth, but the near-term earnings contribution must exceed the additional amortization and integration costs for value creation to become evident. Foreign-exchange gains declined by ¥0.25bn YoY, contributing to the decline in ordinary income and highlighting sensitivity to currency-related non-operating items.

Financial Health

Liquidity is strong, with current assets of ¥71.71bn versus current liabilities of ¥29.02bn, producing a 247.1% current ratio. The quick ratio of 150.3% also indicates that liquidity is sufficient even before relying on inventory realization. Working capital was ¥42.69bn. Cash and deposits were ¥11.51bn, equal to 3.15x short-term debt of ¥3.65bn. Total interest-bearing debt was ¥3.75bn, consisting almost entirely of short-term borrowings, while long-term loans were only ¥0.10bn. The 97.3% short-term debt ratio triggers the refinancing-risk alert because funding maturities are concentrated in the near term. In context, the refinancing risk is moderated materially by the cash balance, strong current ratio, and very high interest coverage, but access to bank facilities remains important for working-capital funding. The reported debt-to-equity ratio was 0.59x, below the 2.0x warning threshold, while interest-bearing debt represented only about 7.1% of total equity. Debt/capital was a conservative 6.6%. Inventories were ¥28.09bn, equivalent to 33.6% of total assets, and increased 8.0% YoY. Inventory days of 92-93 days trigger both high-inventory-days alerts, exceeding the 90-day and 60-day thresholds. For a trading company, inventory is a core working-capital asset, but this level increases exposure to demand volatility, pricing changes, obsolescence, and cash absorption; efficient sell-through is therefore important. Goodwill rose from ¥0.69bn to ¥1.91bn, an increase of ¥1.22bn, principally reflecting the EMAS acquisition in Industrial Products and the Kyushu Mitaka acquisition in Life Science. Goodwill/equity remains low at 3.6% and goodwill/assets at 2.3%, so the balance sheet is not heavily dependent on acquisition value retention. Intangible assets rose 92.3% YoY to ¥2.51bn but remain only 3.0% of total assets. Contract liabilities were ¥8.50bn, providing a meaningful source of operating funding alongside trade payables of ¥13.44bn.

Notable B/S Changes

Goodwill: +¥1.22bn (+178.4%) to ¥1.91bn - acquisition of EMAS SUPPLIES & SERVICES in Industrial Products and Kyushu Mitaka in Life Science; integration and eventual impairment performance should be monitored, though goodwill/equity remains low at 3.6%. Intangible assets: +¥1.21bn (+92.3%) to ¥2.51bn - reflects acquisition-related asset recognition; the balance-sheet concentration remains limited at 3.0% of total assets. Short-term loans: +¥0.74bn (+25.5%) to ¥3.65bn - increases reliance on short-term funding, although cash of ¥11.51bn covers short-term debt by 3.15x. Inventories: +¥2.10bn (+8.0%) to ¥28.09bn - inventory is 33.6% of assets and days rose to 92-93, increasing working-capital and valuation sensitivity. Accounts receivable: -¥1.81bn (-7.7%) to ¥21.87bn - the decline partly offsets higher inventories within operating working capital. Investment securities: -¥1.02bn (-15.2%) to ¥4.53bn - consistent with the ¥0.94bn gain on sales of investment securities recorded in extraordinary income.

Cash Flow Quality

Dividend Sustainability

The full-year dividend forecast is ¥58 per share, compared with forecast EPS of ¥142.31. This implies a forecast dividend payout ratio of approximately 40.8%, below the 60% sustainability benchmark. Q1 basic EPS was ¥70.83, equivalent to 49.8% of full-year forecast EPS, although the quarter included material non-recurring securities-sale gains. The forecast dividend is therefore supported by the stated full-year earnings plan, but the quality of Q1 net-income coverage is weaker than the headline EPS progress rate because ¥0.94bn of gains on sales of investment securities contributed to extraordinary income. Retained earnings of ¥470.45bn provide a substantial accounting equity buffer relative to the forecast dividend commitment.

Risk Assessment

Business risks include Inventory and demand risk: inventories increased 8.0% YoY to ¥28.09bn and inventory days reached 92-93 days. This is the highest-priority operating risk because specialized trading inventory can be exposed to customer-demand changes, pricing pressure, and obsolescence., Margin risk: the 17.4% gross margin is below the stated 20% alert threshold. Thin-margin trading economics require sustained procurement discipline, product mix management, and operating-cost control; SG&A growth of 3.5% exceeded the 0.4% sales decline in Q1., Life Science execution risk: segment profit fell 22.8% YoY and segment margin compressed by roughly 123bp to 4.8%, making recovery in this segment important to consolidated operating-income growth., Foreign-exchange exposure: foreign-exchange gains declined from ¥0.55bn to ¥0.31bn YoY, contributing to the 13.0% decline in ordinary income. Currency movements can continue to affect non-operating earnings., M&A integration risk: the acquisitions of EMAS SUPPLIES & SERVICES and Kyushu Mitaka increased goodwill and intangible assets. Although the goodwill burden is currently low, post-acquisition revenue, margin, and integration execution determine whether the acquired value is realized..

Financial risks include Refinancing concentration: 97.3% of interest-bearing debt is short-term, exceeding the 40% alert threshold. The immediate impact is mitigated by cash equal to 3.15x short-term debt and a 247.1% current ratio, but funding remains dependent on the timely rollover of short-term facilities., Working-capital funding risk: inventories, receivables, and electronic receivables together are substantial relative to assets, which can raise borrowing needs if inventory turns slow or customer collections weaken., Earnings-normalization risk: Q1 net income was lifted by ¥1.01bn of extraordinary income, including ¥0.94bn from securities sales. This gain is not a recurring source of dividend or operating-profit coverage..

Key concerns include The highest likelihood-and-impact concern is elevated inventory days combined with low gross margin, as modest inventory markdowns or slower turnover could have an outsized effect on trading profitability., The second key concern is the gap between falling ordinary income and sharply higher net income, which reflects non-recurring asset monetization rather than underlying earnings acceleration., Short-term debt concentration warrants monitoring despite ample current liquidity, particularly if working-capital requirements rise following acquisitions or inventory accumulation..

Investment Implications

Key takeaways include Q1 operating-income progress was ahead of the standard seasonal benchmark at 30.4% of the full-year plan, despite revenue declining 0.4% YoY., Reported net-income growth of 37.9% was driven primarily by ¥1.01bn of extraordinary gains, so ordinary income and operating income are more relevant measures of recurring momentum., Industrial Products was the largest segment-profit contributor and improved both profit and margin, while Life Science experienced the sharpest profit deterioration., The balance sheet has strong liquidity and low interest-bearing leverage, but inventory intensity and short-term debt concentration require active working-capital management., Acquisition-related goodwill remains modest relative to equity, limiting current balance-sheet impairment exposure, while integration performance remains an operational variable..

Metrics to watch include Inventory days and absolute inventories, currently 92-93 days and ¥28.09bn, Life Science segment revenue, segment profit, and margin, Industrial Products post-acquisition revenue and segment-profit contribution, Recurring ordinary income excluding foreign-exchange volatility and extraordinary securities-sale gains, SG&A growth relative to revenue growth, Short-term debt rollover, cash/short-term debt coverage, and current ratio, Full-year operating-income progress against the ¥6.20bn forecast.

Regarding relative positioning, The company exhibits a conservatively financed balance sheet for a trading-oriented business, with strong liquidity, low debt/capital of 6.6%, and robust interest coverage. Its profitability profile is characterized by relatively thin gross margins but solid annualized ROE, with current reported ROE materially enhanced by non-recurring gains rather than purely recurring operating improvement.